维奈托克与低甲基化药物联合治疗骨髓增殖性肿瘤继发的急性髓系白血病 - Suppr

Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.

作者信息

Tremblay Douglas, Feld Jonathan, Dougherty Mikaela, Czaplinska Tina, Sanchez Gillian, Kremyanskaya Marina, Bar-Natan Michal, Shih Alan H, Keyzner Alla, Mascarenhas John

机构信息

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States.

出版信息

Leuk Res. 2020 Nov;98:106456. doi: 10.1016/j.leukres.2020.106456. Epub 2020 Sep 22.

DOI:10.1016/j.leukres.2020.106456

PMID:33002673

Abstract

摘要

相似文献

Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.维奈托克与低甲基化药物联合治疗骨髓增殖性肿瘤继发的急性髓系白血病

Leuk Res. 2020 Nov;98:106456. doi: 10.1016/j.leukres.2020.106456. Epub 2020 Sep 22.

The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.维奈托克和地西他滨用于治疗相关急性髓系白血病合并晚期非血液系统恶性肿瘤的可行性。

Leuk Res. 2019 Sep;84:106196. doi: 10.1016/j.leukres.2019.106196. Epub 2019 Jul 30.

Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients.维奈托克联合低甲基化药物治疗急变期骨髓增殖性肿瘤：12例患者的初步经验

Br J Haematol. 2020 Dec;191(5):e120-e124. doi: 10.1111/bjh.17084. Epub 2020 Sep 18.

Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).接受去甲基化药物联合维奈克拉（HMA-Ven）或脂质体柔红霉素-阿糖胞苷（CPX-351）治疗的继发性急性髓系白血病的治疗结果

Am J Hematol. 2021 Jun 1;96(6):E196-E200. doi: 10.1002/ajh.26157. Epub 2021 Apr 8.

Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax.继发性急性髓系白血病和早期感染是接受去甲基化药物和维奈克拉治疗的急性髓系白血病患者生存不良的独立预测因素。

Hematol Oncol. 2024 Sep;42(5):e3310. doi: 10.1002/hon.3310.

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.维奈托克联合低甲基化药物治疗急性髓系白血病：梅奥诊所 86 例患者系列研究。

Am J Hematol. 2020 Dec;95(12):1511-1521. doi: 10.1002/ajh.25978. Epub 2020 Sep 16.

Hypomethylating agents and venetoclax in acute myeloid leukemia.急性髓系白血病中的去甲基化药物与维奈克拉

Clin Adv Hematol Oncol. 2021 Feb;19(2):82-83.

Venetoclax with decitabine or azacitidine for AML.维奈托克联合地西他滨或阿扎胞苷治疗急性髓系白血病

Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.维奈克拉与去甲基化药物联合治疗复发/难治性急性髓系白血病的疗效

Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。

Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.

引用本文的文献

Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.单独使用阿扎胞苷或联合使用阿扎胞苷治疗不符合强化化疗或异基因造血细胞移植条件的加速期和急变期骨髓增殖性肿瘤患者的结局——一项FIM研究

Hemasphere. 2025 Sep 4;9(9):e70202. doi: 10.1002/hem3.70202. eCollection 2025 Sep.

SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms.SOHO最新技术进展与后续问题 | 骨髓增殖性肿瘤管理中的挑战性病例

Clin Lymphoma Myeloma Leuk. 2025 Jul;25(7):484-493. doi: 10.1016/j.clml.2025.02.003. Epub 2025 Feb 16.

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.奥拉帕尼在先前骨髓增殖性肿瘤引起的IDH1突变急性髓系白血病中显示出显著的临床活性。

Br J Haematol. 2025 Apr;206(4):1121-1128. doi: 10.1111/bjh.19944. Epub 2024 Dec 19.

Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia.骨髓增殖性肿瘤转化为急性髓系白血病的防治

Haematologica. 2025 Apr 1;110(4):828-839. doi: 10.3324/haematol.2023.283950. Epub 2024 Oct 24.

Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agents.伴有髓外疾病的成年急性髓系白血病患者接受维奈克拉/去甲基化药物治疗的结果

Haematologica. 2025 Feb 1;110(2):378-384. doi: 10.3324/haematol.2024.285985.

How I treat secondary acute myeloid leukemia.我如何治疗继发性急性髓系白血病。

Blood. 2025 Mar 20;145(12):1260-1272. doi: 10.1182/blood.2024024011.

Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.当代加速/急变期骨髓增殖性肿瘤患者的治疗方法和结局。

Blood Adv. 2024 Jul 9;8(13):3468-3477. doi: 10.1182/bloodadvances.2024012880.

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.急变期骨髓增殖性肿瘤：当代综述与 2024 年治疗算法。

Blood Cancer J. 2023 Jul 18;13(1):108. doi: 10.1038/s41408-023-00878-8.

[Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].费城染色体阴性骨髓增殖性肿瘤加速期/急变期患者的临床特征及预后因素

Zhonghua Xue Ye Xue Za Zhi. 2023 Apr 14;44(4):276-283. doi: 10.3760/cma.j.issn.0253-2727.2023.04.003.

Targeted Therapy for MPNs: Going Beyond JAK Inhibitors.骨髓增殖性肿瘤的靶向治疗：超越JAK抑制剂

Curr Hematol Malig Rep. 2023 Jun;18(3):41-55. doi: 10.1007/s11899-023-00690-y. Epub 2023 Jan 27.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献